Liposomal pegylated doxorubicin and oxaliplatin as salvage chemotherapy in patients with metastatic gastric cancer treated earlier

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 559-564

  Recchia, Francesco ^a,b   Candeloro, Giampiero ^a   Guerriero, Gabriele ^b   Piazze, Juan ^b   Desideri, Giovambattista ^c   Necozione, Stefano ^c   Rea, Silvio ^b,c  

^a Ospedale Civile di Avezzano   (Italy)

^b Fondazione Carlo Ferri   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Oxaliplatin; Pegylated liposomal doxorubicin; Pretreated metastatic gastric cancer; Second line chemotherapy

Indexed keywords

DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 2; ISOTRETINOIN; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; EVENING DOSAGE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; METASTATIC GASTRIC CANCER; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOXORUBICIN; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; SALVAGE THERAPY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 77951297576     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328338b6a5     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Cuschieri A,Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al.; Surgical Co-operative Group. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer 1999; 79:1522-1530.
3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725-730.
4. Jemal A, Clegg LX,Ward E, Ries LA,Wu X, Jamison PM, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101:3-27.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006; 24:4991-4997.
6. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:5201-5206.
7. Wilson D, Hiller L, Geh JI. Review of second line chemotherapy for advanced gastric adenocarcinoma. Clin Oncol (R Coll Radiol) 2005; 17:81-90. Review.
8. Kyoto Research Group for Chemotherapy of Gastric Cancer. Randomized, comparative study of combination chemotherapy in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin and 40-epirubicin (FPEPIR). Anticancer Res 1988; 12:1983-1988.
9. Raymond E, Lawrence R, Izbicka E, Faivre S, Von Hoff DD. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res 1998; 4:1021-1029.
10. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol 2008; 26:1435-1442.
11. Smith PJ, Soues S. Multilevel therapeutic targeting by topoisomerase inhibitors. Br J Cancer 1994; 23 (Suppl):s47-s51.
12. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54:987-992.
13. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000; 11:1029-1033.
14. Gnad-Vogt SU, Hofheinz RD, Saussele S, Kreil S, Willer A, Willeke F, et al. Pegylated liposomal doxorubicin and mitomycin C in combination with infusional 5-fluorouracil and sodium folinic acid in the treatment of advanced gastric cancer: results of a phase II trial. Anticancer Drugs 2005; 16:435-440.
15. Recchia F, Saggio G, Candeloro G, Cesta A, Amiconi G, Blasio AD, et al. Chemoimmunotherapy in the treatment of metastatic gastric cancer. Anticancer Drugs 2007; 18:597-604.
16. Recchia F, De Filippis S, Saggio G, Amiconi G, Cesta A, Carta G, et al. Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer. Anticancer Drugs 2003; 14:633-638.
17. Recchia F, Saggio G, Amiconi G, Di Blasio A, Cesta A, Candeloro G, et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol 2007; 106:164-169.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-481.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
21. Recchia F, De Filippis S, Rosselli M, Saggio G, Piccinini M, Rea S. 5-fluorouracil-carboplatin continuous infusion as salvage chemotherapy in advanced cancer. Tumori 2001; 87:383-387.
22. Jeong J, Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, et al. Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol 2008; 19:1135-1140.
23. Zhong H, Zhang Y, Ma S, Ying JE, Yang Y, Yong D, et al. Docetaxel plus oxaliplatin (DOCOX) as a second-line treatment after failure of fluoropyrimidine and platinum in Chinese patients with advanced gastric cancer. Anticancer Drugs 2008; 19:1013-1018.
24. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, et al. A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol 2008; 63:1-8.
25. Park SR, Kook MC, Choi IJ, Kim CG, Lee JY, Cho SJ, et al. Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients. Cancer Chemother Pharmacol 2009. [Epub ahead of print]
26. Mattioli R, Massacesi C, Recchia F, Marcucci F, Cappelletti C, Imperatori L, et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 2005; 16:1147-1151.
27. Recchia F, Rea S, Nuzzo A, Lalli A, Di Lullo L, De Filippis S, et al. Multicenter phase II study of fractionated bimonthly oxaliplatin with leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer, pre-treated with chemotherapy. Oncol Rep 2003; 10:65-69.